Biomedical Engineering Reference
In-Depth Information
60. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M,
Fineman M, et al. (2007) Effects of once-weekly dosing of a
long-acting release formulation of exenatide on glucose con-
trol and body weight in subjects with type 2 diabetes. Diabetes
Care 30, 1487-1493.
61. Jose B, Tahrani AA, Piya MK, Barnet AH. (2010) Exenatide
once weekly: clinical outcomes and patient satisfaction.
Patient Prefer Adherence 4, 313-324.
62. Kim J-G, Baggio LL, Bridon DP, Castaigne J-P, Robitaille MF,
Jett
e L, et al. (2003) Development and characterization of a
glucagon-like peptide 1-albumin conjugate: the ability to
activate the glucagon-like peptide 1 receptor in vivo. Diabetes
52, 751-759.
63. Byetta prescribing information. Amylin Pharmaceuticals, Inc.,
September 2010. Available at http://pi.lilly.com/us/byetta-pi.
pdf (last accessed October 1, 2010).
64. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan
P, et al. (2002) Pharmacokinetics, pharmacodynamics, safety,
and tolerability of a single-dose of NN2211, a long-acting
glucagon-like peptide 1 derivative, in healthy male subjects.
Diabetes Care 25, 1398-1404.
65. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al.
(2005) Synthesis, characterization, and pharmacokinetic stud-
ies of PEGylated glucagon-like peptide-1. Bioconjug. Chem.
16, 377-382.
66. Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano
K. (1991) Pharmacokinetics of recombinant human granulo-
cyte colony-stimulating factor conjugated
75. Kronthaler U, Schmidbauer S, Liebing U, Lang W, Metzner
HJ, Weimer T, et al. (2009) Prolonged half-life of recombinant
factor VIIa fusion protein - single dose study in rabbits. XXII
International Society on Thrombosis and Haemostasis
Congress, Boston, USA, July 11-16, [Abstract P-TH-561].
Available at http://www.isth2009.com/poster_presentations_
thursday.html
(last accessed May 25, 2010).
76. Horn C, Steuber H, Weimer T, Wormsbacher W, Liebing U,
Kuo W-P. (2010) Concept and structure model of factor VIIa
albumin fusion proteins. Haemophilia 16(Suppl. 4), 37
[Abstract 08P19].
77. White GC 2nd, Beebe A, Nielsen B. (1997) Recombinant
factor IX. Thromb. Haemost. 78, 261-265.
78. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger
CA, Seremetis SV, et al. (2002) Pharmacokinetic analysis of
plasma-derived and recombinant F IX concentrates in previ-
ously treated patients with moderate or severe hemophilia B.
Transfusion 42, 190-197.
79. Bjorkman S, Shapiro AD, Berntorp E. (2001) Pharmaco-
kinetics of recombinant factor IX in relation to age of the
patient: implications for dosing in prophylaxis. Haemophilia 7,
133-139.
80. Sheffield WP, Mamdani A, Hortelano G, Gataiance S, Eltring-
ham-Smith L, Begbie ME, et al. (2004) Effects of genetic
fusion of factor IX to albumin on in vivo clearance in mice and
rabbits. Br. J. Haematol. 126, 565-573.
81. Horn C, Steuber H, Metzner HJ, KuoW-P, Weimer T, Schulte S.
(2010) Concept and structure model of factor IX albumin fusion
proteins. Haemophilia 16(Suppl. 4), 36 [Abstract 08P18].
82. Metzner H, Weimer T, Raquet E, Nolte WM, Pragst I, Zollner
S. (2010) Prolonged serum half-life of a recombinant, albumin-
fused, human coagulation factor IX (rIX-FP) in different animal
species. Haemophilia 16(Suppl. 4), 40 [Abstract 08P41].
83. Campos IT, Amino R, Sampaio CA, Auerswald EA, Friedrich T,
Lemaire HG, et al. (2002) Infestin, a thrombin inhibitor presents
in Triatoma infestans midgut, a Chagas' disease vector:
gene cloning, expression and characterization of the inhibitor.
Insect Biochem. Mol. Biol. 32, 991-997.
84. Campos IT, Tanaka-Azevedo AM, Tanaka AS. (2004) Identi-
fication and characterization of a novel factor XIIa inhibitor in
the hematophagous insect, Triatoma infestans (Hemiptera:
Reduvildae). FEBS Lett. 577, 512-516.
85. Schmidbauer S, Nerlich C, Weimer T, Kronthaler U, Metzner
H, Schulte S. (2009) Prevention of thrombotic events by Factor
XIIa inhibitors. 53rd Annual Meeting Society of Thrombosis
and Haemostasis Research, February 4-7, Vienna, Austria,
A22 [Abstract FC9-3].
86. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al.
(2007) Circumventing the heterogeneity and instability of
human serum albumin-interferon-
a
2b fusion protein by alter-
ing its orientation. J. Biotechnol. 131, 245-252.
87. Zhao HL, Xue C, Wang Y, Sun B, Yao XQ, Liu ZM. (2009)
Elimination of the free sulfhydryl group in the human serum
albumin (HSA) moiety of human interferon-
a
2b and HSA
fusion protein increases its stability against mechanical and
thermal stresses. Eur. J. Pharm. Biopharm. 72, 405-411.
to polyethylene
glycol in rats. Cancer Res. 51, 3710-3714.
67. King AB, Armstrong D. (2003) A comparison of basal insulin
delivery: continuous subcutaneous
insulin
infusion versus
glargine. Diabetes Care 26, 1322.
68. Haffner D, Schaefer F, Girard J, Ritz E, Mehis O. (1994)
Metabolic clearance of recombinant human growth hormone in
health and chronic renal failure. J. Clin. Invest. 93, 1163-1171.
69. Sheffield WP, Eltringham-Smith LJ, Gataiance S, Bhakta V.
(2009) A long-lasting, plasmin-activatable thrombin inhibitor
aids clot lysis in vitro and does not promote bleeding in vivo .
Thromb. Haemost. 101, 867-877.
70. Markwardt F, Nowak G, St
€
urzebecher J. (1991) Clinical
pharmacology
of
recombinant
hirudin. Haemostasis
21(Suppl. 1), 133-136.
71. Sheffield WP, Gataiance S, Eltringham-Smith LJ. (2007)
Combined administration of barbourin-albumin and hirudin
- albumin fusion proteins limits fibrin(ogen) deposition on the
rabbit balloon-injured aorta. Thromb. Res. 119, 195-207.
72. World Federation of Hemophilia (WFH). Guidelines for the
Management of Hemophilia. Montreal: World Federation of
Hemophilia; 2005. Available at http://www.wfh.org/2/docs/
Publications/Diagnosis_and_Treatment/Guidelines_Mng_He-
mophilia.pdf (last accessed May 25, 2010).
73. Hedner U, Ingerslev J. (1998) Clinical use of recombinant
FVIIa (rFVIIa). Transfus. Sci. 19, 163-176.
74. Erhardtsen E. (2000) Pharmacokinetics of recombinant
activated factor VII (rFVIIa). Semin. Thromb. Hemost. 26,
385-391.
Search WWH ::
Custom Search